These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18220748)

  • 41. Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
    Westerfeld N; Pluschke G; Zurbriggen R
    Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):50-7. PubMed ID: 17131241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry.
    Krell T; Manin C; Nicolaï MC; Pierre-Justin C; Bérard Y; Brass O; Gérentes L; Leung-Tack P; Chevalier M
    Biotechnol Appl Biochem; 2005 Jun; 41(Pt 3):241-6. PubMed ID: 15377284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment.
    Liu H; Tu Z; Feng F; Shi H; Chen K; Xu X
    Acta Pharm; 2015 Jun; 65(2):105-16. PubMed ID: 26011928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza virosomes as vaccine adjuvant and carrier system.
    Moser C; Müller M; Kaeser MD; Weydemann U; Amacker M
    Expert Rev Vaccines; 2013 Jul; 12(7):779-91. PubMed ID: 23885823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Various carrier system(s)- mediated genetic vaccination strategies against malaria.
    Tyagi RK; Sharma PK; Vyas SP; Mehta A
    Expert Rev Vaccines; 2008 May; 7(4):499-520. PubMed ID: 18444895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
    Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
    Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
    Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
    Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of endosomal escape peptides on in vitro gene delivery of polyethylene glycol-based vehicles.
    Moore NM; Sheppard CL; Barbour TR; Sakiyama-Elbert SE
    J Gene Med; 2008 Oct; 10(10):1134-49. PubMed ID: 18642401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Virosome: An engineered virus for vaccine delivery.
    Ali H; Akbar M; Iqbal B; Ali F; Sharma NK; Kumar N; Najmi A; Albratty M; Alhazmi HA; Madkhali OA; Zoghebi K; Alam MS
    Saudi Pharm J; 2023 May; 31(5):752-764. PubMed ID: 37181145
    [No Abstract]   [Full Text] [Related]  

  • 50. Influenza virosomes as a vaccine adjuvant and carrier system.
    Moser C; Amacker M; Zurbriggen R
    Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted gene delivery by virosomes.
    Sarkar DP; Ramani K; Tyagi SK
    Methods Mol Biol; 2002; 199():163-73. PubMed ID: 12094567
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of substitution of hemagglutinin-neuraminidase with influenza hemagglutinin on Sendai virus F protein mediated membrane fusion.
    Bagai S; Sarkar DP
    FEBS Lett; 1994 Oct; 353(3):332-6. PubMed ID: 7957887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
    Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
    Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs).
    Glück R
    Vaccine; 1999 Mar; 17(13-14):1782-7. PubMed ID: 10194840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Endosome Escape Strategies for Improving the Efficacy of Oligonucleotide Delivery Systems.
    Wan Y; Moyle PM; Toth I
    Curr Med Chem; 2015; 22(29):3326-46. PubMed ID: 26303176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced immune responses induced by vaccine using Sendai virosomes as carrier.
    Li Q; Gao JQ; Qiu LY; Cui FD; Jin Y
    Int J Pharm; 2007 Feb; 329(1-2):117-21. PubMed ID: 17046184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virosomal adjuvanted antigen delivery systems.
    Moser C; Metcalfe IC; Viret JF
    Expert Rev Vaccines; 2003 Apr; 2(2):189-96. PubMed ID: 12899570
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mucosal antibody response induced with a nasal virosome-based influenza vaccine.
    Durrer P; Glück U; Spyr C; Lang AB; Zurbriggen R; Herzog C; Glück R
    Vaccine; 2003 Oct; 21(27-30):4328-34. PubMed ID: 14505915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reconstituted Sendai virus envelopes as biological carriers: dual role of F protein in binding and fusion with liver cells.
    Bagai S; Sarkar DP
    Biochim Biophys Acta; 1993 Oct; 1152(1):15-25. PubMed ID: 8399293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.